-
1.发明公开公开(公告)号：US20230399621A1
公开(公告)日：2023-12-14
申请号：US18331042
申请日：2023-06-07
发明人： Thomas ICHIM , Amit PATEL , Courtney BARTLETT
IPC分类号： C12N5/0775 , C12N5/00
CPC分类号： C12N5/0662 , C12N5/0018 , C12N2501/165 , C12N2501/155 , C12N2501/145 , C12N2501/125 , C12N2501/22 , C12N2501/2303 , C12N2501/2306
摘要： Disclosed are means, methods and compositions of matter useful for generation of conditioned media from mesenchymal stem cells (MSC). In one embodiment MSC are extracted, dedifferentiated into inducible pluripotent stem cells (iPSC) and said iPSC are differentiated into the MSC lineage. The differentiated MSC are utilized as producers of conditioned media for therapeutic purposes. In one embodiment MSC are subjected to one or more stressors, after which conditioned media is extracted and in some cases concentrated. Said conditioned media can be utilized as a therapeutic agent or can be used in the generation of immune modulatory cells.
-
2.发明公开公开(公告)号：US20230392113A1
公开(公告)日：2023-12-07
申请号：US18331029
申请日：2023-06-07
发明人： Thomas ICHIM , Amit PATEL , Courtney BARTLETT
IPC分类号： C12N5/0735
CPC分类号： C12N5/0606 , C12N2500/30 , C12N2506/45
摘要： Disclosed are methods, compositions of matter and protocols useful for restoring/enhancing endometrial function by administration of regenerative cells. In one embodiment cells capable of decreasing fibrosis, stimulation of angiogenesis, and augmenting hormone responsiveness are administered systemically or locally. In some embodiments cells utilized are autologous or allogeneic mesenchymal stem cells.
-
公开(公告)号：US20230218671A1
公开(公告)日：2023-07-13
申请号：US18082841
申请日：2022-12-16
发明人： Thomas Ichim , Amit Patel , Timothy Warbington
摘要： Disclosed are novel method of inducing tissue regeneration through administration of gamma delta T cells that have been endowed regenerative activity. In one embodiment said regenerative active is bestowed upon said cells by culture with a regenerative cell population. In other embodiments a chimeric antigen receptor (CAR) is transfected which induces generation of regenerative substances upon activation of said CAR. Regenerative factors useful for the treatment of the invention depend on the condition for which treatment is desired, for example, in neurological conditions production of brain derived neurotrophic factor is produced upon activation of said CAR, wherein said CAR recognizes antigens or neoantigens associated with neuronal injury.
-
公开(公告)号：US20230014637A1
公开(公告)日：2023-01-19
申请号：US17865881
申请日：2022-07-15
发明人： Thomas Ichim , Amit Patel
IPC分类号： C12N5/0775
摘要： Disclosed are novel cellular populations generated by explosion of monocytic cells to conditioned media of regenerative cells. In one embodiment said regenerative cells are umbilical cord endothelial cells and said cells are pre-activated to possess enhance ability to reprogram said monocytic lineage cells. In one embodiment monocyte lineage cells are collected from leukopaks by plastic adherence and subsequently cultured in a manner to generate cells similar to M2 cells. In one embodiment said monocytic cells are cultured in a manner to generate myeloid derived suppressor cells. In one embodiment cells are generated to reducing inflammatory conditions. In another embodiment cells are generated for treatment of degenerative conditions. In another embodiment cells are generated for treatment of fibrosis.
-
5.发明申请公开(公告)号：US20180360882A1
公开(公告)日：2018-12-20
申请号：US16009982
申请日：2018-06-15
发明人： Thomas Ichim , Amit Patel
IPC分类号： A61K35/17 , C07K14/71 , C12N5/0783 , C07K14/435 , A61K35/28 , A61K9/00 , A61K38/19 , A61K38/45 , A61K38/22
摘要： Disclosed are method of enhancing perispinal perfusion in a patient suffering from reduced perfusion of the lower back through administration of T regulatory cells alone capable of stimulating angiogenesis directly or through enhancement of angiogenic activities of cellular therapies. Said cellular therapies possessing angiogenic activities include mesenchymal stem cells, hematopoietic stem cells and endothelial progenitor cells. In one embodiment of the invention, administration of T regulatory cells is performed that are expanded ex vivo. For certain embodiment of the invention T regulatory cells may be autologous or allogeneic.
-
6.发明申请公开(公告)号：US20180071342A1
公开(公告)日：2018-03-15
申请号：US15702735
申请日：2017-09-12
发明人： Thomas Ichim , Amit Patel
IPC分类号： A61K35/50 , C12N5/073 , C12N5/0775
CPC分类号： A61K35/50 , C12N5/0605 , C12N5/0668 , C12N2510/00
摘要： Disclosed are means of inducing and accelerating neurological recovery subsequent to a stroke through administration of amniotic fluid derived stem cells. In one embodiment stem cells are isolated from amniotic fluid and expanded under conditions allowing for expression of SSEA3, SSEA4, Tra1-60, Tra1-81, Tra2-54, Oct-4 and CD105. Said cells are subsequently administered into a patient having undergone a stroke, so as to induce direct regeneration (through transdifferentiation and replacement of neural tissue), as well as indirect regeneration (through production of growth factors that augment endogenous regenerative mechanisms while inhibiting degenerative mechanisms). In some embodiments factors produced by said amniotic fluid stem cells may be utilized instead of cells themselves. Said factors may include proteins, peptides, conditioned media, exosomes, or microvesicles.
-
7.发明公开公开(公告)号：US20240339176A1
公开(公告)日：2024-10-10
申请号：US18630510
申请日：2024-04-09
摘要： Disclosed are systems, means and compositions of matter utilizing artificial intelligence to create unique cells and/or organs from pluripotent stem cells. In one embodiment an artificial intelligence/machine learning approach is utilized to overview and categorize molecular and cellular data regarding normal embryonic development and associated pathways. Through acquiring this information, said artificial intelligence/machine learning system develops a graded list of morphogens/differentiating agents and/or conditions that are utilized to replicate the process of cell/tissue/organ formation artificially. In one embodiment the invention teaches generation of artificial pancreatic organoids through growth factors predicted by said artificial intelligence/machine learning systems. In other embodiments embryogenesis is recapitulated in adult tissue using predicted morphogens and/or extracellular matrix treatments.
-
8.发明公开公开(公告)号：US20230399626A1
公开(公告)日：2023-12-14
申请号：US18331048
申请日：2023-06-07
发明人： Thomas ICHIM , Amit PATEL , Courtney BARTLETT
IPC分类号： C12N5/071
CPC分类号： C12N5/0692 , C12N2501/60
摘要： Disclosed are means, methods and compositions of matter useful for generation of conditioned media from endothelial progenitor cells (EPC). In one embodiment, EPC are extracted, dedifferentiated into inducible pluripotent stem cells (iPSC) and said iPSC are differentiated into the EPC lineage. The differentiated EPC are utilized as producers of conditioned media for therapeutic purposes. In one embodiment EPC are subjected to one or more stressors, after which conditioned media is extracted and in some cases concentrated. Said conditioned media can be utilized as a therapeutic agent or can be used in the generation of immune modulatory cells.
-
公开(公告)号：US20230374463A1
公开(公告)日：2023-11-23
申请号：US18311768
申请日：2023-05-03
发明人： Thomas ICHIM , Amit PATEL , Courtney BARTLETT
IPC分类号： C12N5/0775
CPC分类号： C12N5/0662 , C12N2506/45 , C12N2500/02
摘要： Disclosed are compositions of matter, protocols, and procedures useful for generation of mesenchymal stem cells capable of withstanding the microenvironment of degenerating ovaries. In one embodiment mesenchymal stem cells are pre-treated under conditions capable of upregulating cytoprotective responses and genes, such as HIF-1 alpha and hemoxygenase. In other embodiments mesenchymal stem cells are temporarily pulsed with hypoxia and/or acidity in order to prime them for the harsh environment of degenerating ovarian tissue. Through this approach increased viability of mesenchymal stem cell subsequent to intra-ovarian administration is achieved.
-
公开(公告)号：US20230366876A1
公开(公告)日：2023-11-16
申请号：US18315364
申请日：2023-05-10
发明人： Thomas ICHIM , Amit PATEL , Courtney BARTLETT
CPC分类号： G01N33/5044 , A61K35/28
摘要： Disclosed are means and methods useful in selecting osteoarthritis patients most likely to respond to regenerative medicine therapy. One means of practicing the invention is to determine quantity and quality of inflammatory exosomes generated from the tissue adjacent to the injured cartilage. In another embodiment the invention provides detection of exosomes produced by inflammatory processes local or systemic to the body. In some embodiments therapies are tailored to the extent of inflammatory exosomes.
-
-
-
-
-
-
-
-
-
搜索结果
53 条记录 (耗时 0.028 秒)
